Impact of Menopause in Patients with Multiple Sclerosis: Current Perspectives

Overview

Journal Int J Womens Health

Publisher Dove Medical Press

Specialty Gynecology & Obstetrics

Date 2023 Feb 1

PMID 36721498

Authors

Lorena Lorefice

Maurizio Nicola DAlterio

Davide Firinu

Giuseppe Fenu

Eleonora Cocco

Affiliations

Soon will be listed here.

Abstract

Given the aging population, with a peak age-specific prevalence that is shifting beyond the age of 50, several women currently living with MS are very close to menopause. Menopause is usually characterized by several specific symptoms with adverse impacts on different aspects of a woman's quality of life, such as fatigue, and cognitive, mood and bladder disorders, which overlap with symptoms of MS. Generally, after this biological transition, women with MS appear to be subject to less inflammatory activity. However, several studies have reported an increase of disability accumulation after menopause, suggesting that it is a turning point to a more progressive phase of the disease. This may be attributable to the hormonal and immunological changes associated with menopause, with several effects on neuroinflammation and neurodegeneration increasing due to the immunosenescence of aging. This review summarizes the hormonal and immunological changes associated with menopause, detailing the effects on MS symptoms, outcomes, and the aging process. Furthermore, possible interventions to improve patients' quality of life are evaluated. In fact, it is increasingly necessary to improve the global management of MS women, as well as their lives, at this multifaceted turning point.

Citing Articles

The influence of menopause on multiple sclerosis.

Simonsen C, Flemmen H, Broch L, Myklebust H, Berg-Hansen P, Brunborg C Eur J Neurol. 2024; 32(1):e16566.

PMID: 39601490 PMC: 11625929. DOI: 10.1111/ene.16566.

Global prevalence of fatigue in patients with multiple sclerosis: a systematic review and meta-analysis.

Yi X, Zhang Y, Du Q, Kang J, Song S, Li T Front Neurol. 2024; 15:1457788.

PMID: 39416662 PMC: 11479926. DOI: 10.3389/fneur.2024.1457788.

Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review.

Fernandez O, Soelberg Sorensen P, Comi G, Vermersch P, Hartung H, Leocani L Front Immunol. 2024; 15:1379538.

PMID: 38646534 PMC: 11032020. DOI: 10.3389/fimmu.2024.1379538.

Letter to the Editor: "Concurrent multi-session anodal trans-cranial direct current stimulation enhances pelvic floor muscle training effectiveness for female patients with multiple sclerosis suffering from urinary incontinence and pelvic floor....

Ozden F Int Urogynecol J. 2023; 35(5):1101-1102.

PMID: 37747551 DOI: 10.1007/s00192-023-05651-w.

Menopausal transition in multiple sclerosis: relationship with disease activity and brain volume measurements.

Lorefice L, Fenu G, Fronza M, Murgia F, Frau J, Coghe G Front Neurol. 2023; 14:1251667.

PMID: 37602270 PMC: 10434500. DOI: 10.3389/fneur.2023.1251667.

References

Bove R, Gilmore W . Hormones and MS: Risk factors, biomarkers, and therapeutic targets. Mult Scler. 2018; 24(1):17-21. DOI: 10.1177/1352458517737396. View

Genazzani A, Pluchino N, Luisi S, Luisi M . Estrogen, cognition and female ageing. Hum Reprod Update. 2006; 13(2):175-87. DOI: 10.1093/humupd/dml042. View

Magyari M, Soelberg Sorensen P . Comorbidity in Multiple Sclerosis. Front Neurol. 2020; 11:851. PMC: 7473304. DOI: 10.3389/fneur.2020.00851. View

Bove R, Chitnis T . The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis. Mult Scler. 2014; 20(5):520-6. DOI: 10.1177/1352458513519181. View

Kalincik T, Vivek V, Jokubaitis V, Lechner-Scott J, Trojano M, Izquierdo G . Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. Brain. 2013; 136(Pt 12):3609-17. DOI: 10.1093/brain/awt281. View

Magyari M, Koch-Henriksen N . Quantitative effect of sex on disease activity and disability accumulation in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2022; 93(7):716-722. PMC: 9279846. DOI: 10.1136/jnnp-2022-328994. View

Whitacre C . Sex differences in autoimmune disease. Nat Immunol. 2001; 2(9):777-80. DOI: 10.1038/ni0901-777. View

Cocco E, Sardu C, Gallo P, Capra R, Amato M, Trojano M . Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. Mult Scler. 2008; 14(9):1225-33. DOI: 10.1177/1352458508094882. View

Brochet B, Ruet A . Cognitive Impairment in Multiple Sclerosis With Regards to Disease Duration and Clinical Phenotypes. Front Neurol. 2019; 10:261. PMC: 6435517. DOI: 10.3389/fneur.2019.00261. View

10.

Bove R, Healy B, Secor E, Vaughan T, Katic B, Chitnis T . Patients report worse MS symptoms after menopause: findings from an online cohort. Mult Scler Relat Disord. 2015; 4(1):18-24. DOI: 10.1016/j.msard.2014.11.009. View

11.

Golden L, Voskuhl R . The importance of studying sex differences in disease: The example of multiple sclerosis. J Neurosci Res. 2016; 95(1-2):633-643. PMC: 5825192. DOI: 10.1002/jnr.23955. View

12.

Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S . Multiple sclerosis. Nat Rev Dis Primers. 2018; 4(1):43. DOI: 10.1038/s41572-018-0041-4. View

13.

Bove R, Secor E, Chibnik L, Barnes L, Schneider J, Bennett D . Age at surgical menopause influences cognitive decline and Alzheimer pathology in older women. Neurology. 2013; 82(3):222-9. PMC: 3902759. DOI: 10.1212/WNL.0000000000000033. View

14.

Manson J, Chlebowski R, Stefanick M, Aragaki A, Rossouw J, Prentice R . Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013; 310(13):1353-68. PMC: 3963523. DOI: 10.1001/jama.2013.278040. View

15.

Randolph Jr J, Zheng H, Sowers M, Crandall C, Crawford S, Gold E . Change in follicle-stimulating hormone and estradiol across the menopausal transition: effect of age at the final menstrual period. J Clin Endocrinol Metab. 2010; 96(3):746-54. PMC: 3047231. DOI: 10.1210/jc.2010-1746. View

16.

Lorefice L, Fronza M, Fenu G, Frau J, Coghe G, DAlterio M . Effects of Pregnancy and Breastfeeding on Clinical Outcomes and MRI Measurements of Women with Multiple Sclerosis: An Exploratory Real-World Cohort Study. Neurol Ther. 2021; 11(1):39-49. PMC: 8857366. DOI: 10.1007/s40120-021-00297-6. View

17.

Ladeira F, Salavisa M, Caetano A, Barbosa R, Sa F, Correia A . The Influence of Menopause in Multiple Sclerosis Course: A Longitudinal Cohort Study. Eur Neurol. 2019; 80(3-4):223-227. DOI: 10.1159/000496374. View

18.

Cosman F, de Beur S, LeBoff M, Lewiecki E, Tanner B, Randall S . Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int. 2014; 25(10):2359-81. PMC: 4176573. DOI: 10.1007/s00198-014-2794-2. View

19.

Koch-Henriksen N, Thygesen L, Stenager E, Laursen B, Magyari M . Incidence of MS has increased markedly over six decades in Denmark particularly with late onset and in women. Neurology. 2018; 90(22):e1954-e1963. DOI: 10.1212/WNL.0000000000005612. View

20.

Bove R, Healy B, Musallam A, Glanz B, De Jager P, Chitnis T . Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort. Mult Scler. 2015; 22(7):935-43. PMC: 4824677. DOI: 10.1177/1352458515606211. View